Presentation

BioGaia is a Swedish healthcare firm founded in 1990 with nearly 30 years of experience within the field of probiotic products. The company has about 160 employees and offices in Sweden, the US as well as Japan and Singapore. BioGaia engages in the development, marketing, and sale of probiotic products with documented health benefits. The portfolio consists of 555 patents in 30 families and the products are sold in 100 different markets through distributors.

Recent highlights
During Q2, sales amounted to SEK 288M with an increase of 42%. The sales for Q2 has been positively impacted by an increased demand mainly from the European market.
In December, BioGaia acquired its US distributor Nutraceutics to strengthen the market position. In February, a randomised controlled study showed that BioGaia’s probiotic strain significantly reduced inflammation and hospital stay in patients with acute uncomplicated diverticulitis. In May and June, BioGaia started its own distribution in Canada and signed an exclusive agreement in South Korea to sell its probiotic drops for infants. Recently in July, BioGaia launched a new probiotic product Pharentis to support children’s respiratory health.

Outlook
BioGaia aims to continue implementing their omnichannel marketing strategy with strengthened digitalisation and consumer-oriented communication and a strong focus on science & product development.